Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients
This article was originally published in The Gray Sheet
Executive Summary
Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.
You may also be interested in...
Boston Scientific Sees Return To Double-Digit Growth In Second Half Of 2000
Resumption of Boston Scientific's historic 20%-plus annual sales growth rate will occur the second half of 2000, the company is assuring investors, as key holes in the firm's product pipeline are filled early in the year, including release of advanced coronary stent systems.
Medtronic AneuRx Endovascular AAA Graft Should Be Approved - FDA Panel
Medtronic's AneuRx minimally invasive endovascular graft for abdominal aortic aneurysm repair was successfully implanted in 98% of the 416 patients treated in the company's pivotal trial to support premarket approval, study investigators said.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.